Marshall Wace North America’s Amicus Therapeutics FOLD Stock Holding History

Marshall Wace North America’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-12,531	Closed	-$124K	–	1563
2021 Q1	$124K	Sell	12,531 -11,937	-49%	-$185K	﹤0.01%	1439
2020 Q4	$565K	Buy	+24,468	New	+$500K	﹤0.01%	1064
2019 Q4	–	Sell	-2,109,899	Closed	-$16.9M	–	1382
2019 Q3	$16.9M	Sell	2,109,899 -4,598,329	-69%	-$49.9M	0.1%	191
2019 Q2	$83.7M	Buy	6,708,228 +278,209	+4%	+$3.53M	0.52%	46
2019 Q1	$87.4M	Buy	6,430,019 +1,113,735	+21%	+$13.6M	0.62%	42
2018 Q4	$50.9M	Buy	5,316,284 +2,247,605	+73%	+$24.7M	0.49%	61
2018 Q3	$37.1M	Buy	3,068,679 +2,863,872	+1,398%	+$40.1M	0.25%	97
2018 Q2	$3.2M	Buy	204,807 +118,032	+136%	+$1.78M	0.02%	634
2018 Q1	$1.3M	Sell	86,775 -85,280	-50%	-$1.3M	0.01%	929
2017 Q4	$2.48M	Sell	172,055 -45,282	-21%	-$622K	0.01%	782
2017 Q3	$3.26M	Buy	+217,337	New	+$2.88M	0.02%	668

Other funds holding FOLD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Marshall Wace North America's FOLD Position: Q2 2021 in Review

Marshall Wace North America sold out of Amicus Therapeutics (FOLD) in Q2 2021, closing a stake of 12,531 shares — an estimated $124K sold.

Marshall Wace North America first reported a position in FOLD in Q3 2017 and held it in 11 quarters. The position peaked at $87.4M in Q1 2019. 235 funds tracked by Wall St. Rank hold FOLD as of Q2 2021.

Marshall Wace North America reported no remaining Amicus Therapeutics position as of Q2 2021 after selling out during the quarter.
Marshall Wace North America sold 12,531 Amicus Therapeutics shares in Q2 2021, an estimated $124K.
Marshall Wace North America first reported a position in Amicus Therapeutics in Q3 2017 and held it in 11 quarters.
Marshall Wace North America's Amicus Therapeutics position peaked at $87.4M in Q1 2019.
235 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2021.

Based on Marshall Wace North America's 13F filing for Q2 2021, filed 13 Aug 2021.